Posted by Social Science Research Network
Determinants of Pharmaceutical Review, Success and Duration – Rosa M. Abrantes-Metz (Global Economics Group, LLC ; New York University – Leonard N. Stern School of Business – Department of Economics), Christopher Adams (Federal Trade Commission – Bureau of Economics) and Albert D. Metz (Moody’s Investors Service)
ABSTRACT: This paper estimates three duration models, one for each of the three clinical phases of drug development using publicly available data. Specifically, we estimate three discrete time mixed proportional hazard models, with some parameter constraints across models. We present the estimated relationship between particular drug characteristics and the probability of succeeding (and failing) each of the clinical review phases, as well as the expected duration of review. The characteristics we control for include, among others, primary indication, route of administration, and original material as well as fixed effects for vaccines and reformulations. We are also able to identify spill-over effects from sponsorship or licensing by large pharmaceutical companies, and the effect of “competition” in the form of same-disease drugs already in the review process. Additionally, we distinguish drugs being developed in the U.S., versus those who are likely developed abroad. Calendar time fixed-effects (both annual and quarterly) are also estimated which permit us to identify whether average durations are changing independently of the changing profile of the drugs under review, in other words, whether they are changing as a result of policy for example.
On balance we find that primary disease indications are usually unrelated to a drug’s eventual success or failure in review, but that different original materials and different routes of administration are significant. Competition in each of the phases is a determinant factor in both success and failure. Spillover effects seem to have a small impact, and so does being sponsored by a large pharmaceutical company, and being licensed by one. A major finding of our paper is that drugs developed only in the U.S. versus in the U.S. and in other countries simultaneously, move through the review process faster, but also have a lower probability of succeeding. This model can be used to simulate the path of drugs through the pipeline, and can be used in a variety of situations, including antitrust review, intellectual property, insurance, market valuation and social policy analysis.
Featured News
Google and South Carolina Clash Over State Records Demand
May 8, 2024 by
CPI
Telefonica Germany Teams Up with Amazon Web Services to Migrate 5G Customers
May 8, 2024 by
CPI
Federal Judge Grants $7.4 Million Settlement in Pork Price-Fixing Case
May 8, 2024 by
CPI
Wilson Sonsini Bolsters Antitrust and Competition Practice with Key Partner Returns
May 8, 2024 by
CPI
EU to Scrutinize Telecom Italia’s Network Sale to KKR
May 8, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI